Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06684847 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
A Phase 3 study of Primary Sjogren's Disease, sponsored by argenx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT06684847 is a Phase 3 study of Primary Sjogren's Disease that is actively recruiting participants, run by argenx. The registered enrollment target is 580 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT06684847, a Phase 3 study of Primary Sjogren's Disease, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Conditions Studied
Interventions
- OTHER Placebo PH20 SC
- BIOLOGICAL Efgartigimod PH20 SC
Study Locations (20)
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- Centre for Rheumatology, Immunology and Arthritis - Fort Lauderdale
- Finlay Medical Research Corp - Greenacres City
- University of Florida College of Medicine Jacksonville - Jacksonville
- Life Clinical Trials - Margate
- Clinical Research of West Florida, Inc. - Tampa
- Conquest Research - Winter Park
Illinois
- Chicago Clinical Research Institute - Chicago
- Great Lakes Clinical Trials, LLC Ravenswood dba Flourish Research - Chicago
- Chicago Arthritis & Regenerative Medicine - Chicago
- Greater Chicago Specialty Physicians LLC - Orland Park
- Arizona Arthritis & Rheumatology Research, PLLC - Willowbrook
Arizona
- One of a Kind Clinical Research Center LLC - Scottsdale
- Arizona Arthritis & Rheumatology Research, PLLC - Sun City
- Arizona Arthritis & Rheumatology Research, PLLC - Tucson
California
- Providence Medical Foundation - Fullerton
- Stanford University School of Medicine - Stanford
Colorado
- University of Colorado - Aurora
Georgia
- Piedmont Healthcare, Inc. - Atlanta
Idaho
- St. Luke's Clinic - Rheumatology - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06684847
The ClinicalTrials.gov registry entry for NCT06684847 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sjogren's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo PH20 SC is the first listed.
NCT06684847 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT06684847 about?
NCT06684847 is a clinical study titled "A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome". The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration f...
What is the current status of trial NCT06684847?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2025-01-15. Estimated completion is 2028-07.
What conditions does trial NCT06684847 study?
This clinical trial studies the following conditions: Primary Sjogren's Disease.
What interventions are being tested in trial NCT06684847?
The interventions under investigation include: Placebo PH20 SC (OTHER), Efgartigimod PH20 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT06684847?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06684847 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sjogren's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.